Rankings
▼
Calendar
TEVA Q3 2019 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$36B
Q3 2019 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$4.3B
-5.9% YoY
Gross Profit
$1.8B
42.9% margin
Operating Income
-$81M
-1.9% margin
Net Income
-$314M
-7.4% margin
EPS (Diluted)
$-0.29
QoQ Revenue Growth
-1.7%
Cash Flow
Operating Cash Flow
$325M
Free Cash Flow
$156M
Stock-Based Comp.
$35M
Balance Sheet
Total Assets
$57.2B
Total Liabilities
$42.3B
Stockholders' Equity
$13.8B
Cash & Equivalents
$1.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$4.3B
$4.5B
-5.9%
Gross Profit
$1.8B
$2.0B
-9.5%
Operating Income
-$81M
$16M
-606.3%
Net Income
-$314M
-$208M
-51.0%
Revenue Segments
International Markets
$736M
70%
Other Activities
$314M
30%
Geographic Segments
North America
$1.7B
59%
Europe
$1.2B
41%
← FY 2019
All Quarters
Q4 2019 →